Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ovide-Henri Bernadotte

Child & Adolescent Psychiatry Clewiston, FL Medical Doctor

NPI 1598777294 CMS profile 163429

601 W Alverdez Ave, Clewiston, FL 33440

Open in the dashboard

General payments

$8,062

497 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ovide-Henri Bernadotte of Clewiston, FL is reported in the CMS Open Payments database as having received $8,062 across 497 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,023 120
2024 General $1,683 119
2023 General $1,856 116
2022 General $1,266 67
2021 General $694 42
2020 General $269 18
2019 General $271 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ovide-Henri Bernadotte
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Ovide-Henri Bernadotte were reported at $2,023. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Ovide-Henri Bernadotte Child & Adolescent Psychiatry median Middle half National median
2019 $271 $129 $42–$419 $163
2020 $269 $81 $28–$226 $114
2021 $694 $115 $31–$326 $132
2022 $1,266 $124 $40–$382 $149
2023 $1,856 $130 $45–$420 $160
2024 $1,683 $141 $42–$490 $164
2025 $2,023 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $1,593 156 payments
  2. AbbVie, Inc. $1,031 54 payments
  3. Otsuka America Pharmaceutical, Inc. $830 37 payments
  4. Neurocrine Biosciences, Inc. $783 36 payments
  5. ITI, Inc. $718 44 payments
  6. Janssen Pharmaceuticals, Inc $567 28 payments
  7. Teva Pharmaceuticals USA, Inc. $415 29 payments
  8. Alkermes, Inc. $403 19 payments
  9. Ironshore Pharmaceuticals Inc. $220 14 payments
  10. E.R. Squibb & Sons, L.L.C. $209 12 payments
  11. Other $1,292 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,049 495 payments
  2. Education $12 2 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $940 50 payments
  2. QELBREE Psychology $809 60 payments
  3. Qelbree Viloxazine Hydrochloride $784 96 payments
  4. ABILIFY MAINTENA $731 32 payments
  5. INGREZZA $716 32 payments
  6. INVEGA SUSTENNA $562 27 payments
  7. CAPLYTA $417 26 payments
  8. LYBALVI $403 19 payments
  9. REXULTI $372 16 payments
  10. ABILIFY ASIMTUFII $335 14 payments
  11. Other $4,206 225 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

497 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record